Key Takeaways
- • Michel Mommejat, president and chief innovation officer of Tokyo genomics company A.D.A.M. Innovations, argued at Sohn Tokyo 2026 that genomic testing should be treated as an ongoing tool rather than a one-time test, since a person's DNA is fixed but what it reveals changes with age, habits and new health data.
- • According to Mommejat, combining genomic data with evolving health information can help catch cancer and other conditions early and guide treatment selection once disease appears.
- • Mommejat identified the one-time testing habit as a core business problem that consumer genomics has not solved, citing 23andMe, formerly listed on Nasdaq, as an example of the sector's challenges.
Summary
Michel Mommejat, president and chief innovation officer of Tokyo-based genomics company A.D.A.M. Innovations, outlined his view of how genomic data should be used at Sohn Tokyo 2026, as reported by Hedge Fund Alpha. He said the most common misconception in the field is that consumers take a genetic test once, review the results and store them away. Mommejat's central point was that while an individual's DNA does not change, the information it can provide does, as people age, as lifestyle habits shift and as new health data accumulates alongside the genetic profile.
On that basis, Mommejat argued that genomics can serve as a continuing tool for detecting cancer and other conditions early, and for selecting the appropriate treatment once a condition is diagnosed. He characterized the one-time testing model as the business problem consumer genomics has yet to solve.
The article references 23andMe, which was then listed on Nasdaq, in connection with that challenge. The primary source excerpt is truncated and does not include further figures, financial metrics or additional details on A.D.A.M. Innovations' products, customers or commercial plans.
On that basis, Mommejat argued that genomics can serve as a continuing tool for detecting cancer and other conditions early, and for selecting the appropriate treatment once a condition is diagnosed. He characterized the one-time testing model as the business problem consumer genomics has yet to solve.
The article references 23andMe, which was then listed on Nasdaq, in connection with that challenge. The primary source excerpt is truncated and does not include further figures, financial metrics or additional details on A.D.A.M. Innovations' products, customers or commercial plans.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.